Evidence map›Paper›PMID 41146005›Full record

ArticleBMC cardiovascular disorders2025

Development and validation of an echocardiographic nomogram for identifying cardiac amyloidosis in patients with left ventricular hypertrophy.

Shichu Liang, Zhiyue Liu, Fanfan Shi, Liping Chen, Dayan Li, Ying Peng, Wenfeng He, Chaohui Du, He Huang

Abstract readValidation StudyMulticenter Study
In one paragraph

Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shichu Liang *Department of Cardiology, West China Hospital, Sichuan University, No.37 GuoXue Alley, Chengdu, 610041, China.
Zhiyue Liu *Department of Cardiology, West China Hospital, Sichuan University, No.37 GuoXue Alley, Chengdu, 610041, China.
Fanfan ShiDepartment of Clinical Research and Management, Center of Biostatistics, Design, Measurement and Evaluation (CBDME), West China Hospital, Sichuan University, Chengdu, China.
Liping ChenDepartment of Cardiology, West China Hospital, Sichuan University, No.37 GuoXue Alley, Chengdu, 610041, China.
Dayan LiDepartment of Cardiology, West China Hospital, Sichuan University, No.37 GuoXue Alley, Chengdu, 610041, China.
Ying PengDepartment of Cardiology, West China Hospital, Sichuan University, No.37 GuoXue Alley, Chengdu, 610041, China.
Wenfeng HeDepartment of Cardiology, West China Hospital, Sichuan University, No.37 GuoXue Alley, Chengdu, 610041, China.
Chaohui DuDepartment of Cardiology, West China Hospital, Sichuan University, No.37 GuoXue Alley, Chengdu, 610041, China.
He HuangDepartment of Cardiology, West China Hospital, Sichuan University, No.37 GuoXue Alley, Chengdu, 610041, China. huanghe@wchscu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEchocardiography is the principal non-invasive imaging modality for screening cardiac amyloidosis (CA). This study aimed to establish a cohort of CA-associated left ventricular hypertrophy (CA-LVH) within a hospital-based population and to develop an echocardiographic identification model for CA using readily available echocardiographic parameters.

methodsThis retrospective nested cohort study involved the collection of clinical and echocardiographic data from three hospitals affiliated with the West China Medical Center, Sichuan University, between January 1, 2008, and December 31, 2023. The relative wall thickness (RWT) was calculated as twice the left ventricular posterior wall thickness (LVPW) divided by the left ventricular internal diameter (LVID). Asymmetric hypertrophy was defined as a ratio of interventricular septal thickness (IVS) to LVPW greater than 1.3. The AMYLI score was computed as the product of RWT and E/e' ratio.

resultsA total of 185 CA patients (183 AL-CA and 2 ATTR-CA) who underwent 309 echocardiography examinations from different time periods with 1,213 echocardiographic data points from in-hospital non-CA-LVH cases matched for age, gender, and body surface area were included. Multivariable logistic regression analysis identified a history of hypertension [odds ratio (OR): 0.04, 95% confidence interval (CI): 0.021-0.073], LVID [OR: 0.927, 95%CI: 0.878-0.977], left ventricular ejection fraction (LVEF) [OR: 0.95, 95%CI: 0.908-0.993], AMYLI score [OR: 1.088, 95%CI: 1.024-1.161], asymmetric hypertrophy [OR: 3.729, 95%CI: 1.884-7.441], granular sparkling [OR: 3.111, 95%CI: 1.355-7.431], small pericardial effusion [OR: 2.77, 95%CI: 1.563-4.937], mild aortic regurgitation [OR: 2.353, 95%CI: 1.278-4.361], mild mitral regurgitation [OR: 4.331, 95%CI: 2.347-8.141], and mild tricuspid regurgitation [OR: 3.837, 95%CI: 2.026-7.358] as independent predictive factors for CA in LVH patients. The predictive factors were used to construct a nomogram model, which demonstrated high accuracy (0.91-0.92), specificity (0.91-0.92), sensitivity (0.90-0.91), positive predictive value (0.73), negative predictive value (0.93-0.98), and Youden index (0.81-0.83).

conclusionThe developed nomogram displayed remarkable predictive accuracy, which has the potential to enhance CA screening via routine echocardiography and strategically guide subsequent diagnostic evaluations.

Indexed as

CardiomyopathiesDecision Support TechniquesEchocardiographyHypertrophy, Left VentricularImmunoglobulin Light-chain AmyloidosisNomogramsVentricular Function, LeftAgedChinaFemaleHumansMaleMiddle AgedPredictive Value of TestsReproducibility of ResultsRetrospective StudiesCardiac amyloidosisEchocardiographyLeft ventricular hypertrophyNomogram

Identifiers

PMID41146005
PMCPMC12557862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.